ArticleChemical biology & drug design2026
Design and Synthesis of Novel 1,2,3-Triazole Conjugates Featuring Hydroxamic Acid and Sulfonamide Moieties: Exploring Dual Pharmacophores for Enhanced Biological Activity.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A new series of N-hydroxy-1-(4-(aryl sulfonamido)phenyl)-1H-1,2,3-triazole-4-carboxamide derivatives (8a-j) were synthesized through a concise multistep route integrating three key pharmacophores: the 1,2,3-triazole core, an aryl sulfonamide moiety, and an N-hydroxycarboxamide group. Biological evaluation demonstrated promising antimicrobial potential for several derivatives. Compounds 8f, 8g, and 8i exhibited notable antibacterial activity against both Gram-positive and Gram-negative bacteria, whereas most analogues showed weak antifungal activity. In the antimalarial assay, compound 8d emerged as the most potent derivative (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.